Alzheimer disease and type 2 diabetes mellitus: The link to tyrosine hydroxylase and probable nutritional strategies

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 467-477

  Aliev, Gjumrakch ^a,b   Shahida, Khan ^c   Gan, Siew Hua ^d   Firoz, Ck ^c   Khan, Aziz ^c   Abuzenadah, Adel M ^c   Kamal, Warda ^e   Kamal, Mohammad A ^c   Tan, Yi ^f   Qu, Xianqin ^f   Reale, Marcella ^g  

^a GALLY International Biomedical Research Consulting LLC   (United States)

^b University of Atlanta   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^e Enzymoics   (Australia)

^f UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^g UNIVERSITY OF CHIETI   (Italy)

Author keywords

Alzheimer disease; Nutritional strategies; Type 2 diabetes mellitus; Tyrosine hydroxylase

Indexed keywords

AMYLOID PRECURSOR PROTEIN; DOPAMINE; GLUCOSE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TETRAHYDROBIOPTERIN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; TYROSINE 3 MONOOXYGENASE; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BRAIN DEVELOPMENT; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM FUNCTION; CHEMICAL STRUCTURE; CLINICAL FEATURE; COGNITION; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; HYPOTHALAMUS FUNCTION; INFLAMMATION; INSULIN METABOLISM; INSULIN RESISTANCE; MEDITERRANEAN DIET; MOLECULAR GENETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; ANIMAL; DIABETES MELLITUS, TYPE 2; DIET THERAPY; GENETICS; HIPPOCAMPUS; METABOLISM; PATHOLOGY; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DIABETES MELLITUS, TYPE 2; HIPPOCAMPUS; HUMANS; INFLAMMATION; NUTRITION THERAPY; TYROSINE 3-MONOOXYGENASE;

EID: 84904472228     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660153     Document Type: Review

References (113)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Prac 2011; 94(3): 311-21.
2. Tang DL, Zhou X, Li X, Zhao L, Liu F. Variation of mitochondrial gene and the association with type 2 diabetes mellitus in a Chinese population. Diabetes Res Clin Pract 2006; 73(1): 77-82.
3. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34(3): 267-73.
4. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997; 145(4): 301-8.
5. Jellinger KA. Alzheimer 100--highlights in the history of Alzheimer research. J Neural Transm 2006; 113(11): 1603-23.
6. Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007; 56(2): 384-402.
7. Ahmed I, Goldstein BJ. Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Mt Sinai J Med 2006; 73(5): 759-68.
8. Guo JT, Yu J, Grass D, de Beer FC, Kindy MS. Inflammationdependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci 2002; 22(14): 5900-9.
9. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116(7): 1793-801.
10. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007; 13(12): RA214-21.
11. Sridhar GR, Thota H, Allam AR, et al. Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids Health Dis 2006; 5: 28.
12. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217(4558): 408-14.
13. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2(8000): 1403.
14. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215(4537): 1237-9.
15. Tsang SWY, Lai MKP, Kirvell S, et al. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol Aging 2006; 27(9): 1216-23.
16. Tsang SWY, Pomakian J, Marshall GA, et al. Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. Neurobiol Aging 2007; 28(9): 1381-7.
17. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008; 585(1): 97-108.
18. Yaffe K, Blackwell T, Kanaya AM, et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63(4): 658-63.
19. Cole AR, Astell A, Green C, Sutherland C. Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 2007; 31(7): 1046-63.
20. Nicolls M. The Clinical and Biological Relationship between Type II Diabetes Mellitus and Alzheimers Disease. Curr Alzheimer Res 2004; 1(1): 47-54.
21. McNay EC, Recknagel AK. Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem 2011; 96(3): 432-42.
22. Conrad CD, McLaughlin KJ, Harman JS, et al. Chronic Glucocorticoids Increase Hippocampal Vulnerability to Neurotoxicity under Conditions That Produce CA3 Dendritic Retraction But Fail to Impair Spatial Recognition Memory. J Neurosci 2007; 27(31): 8278-85.
23. Nichols NR, Zieba M, Bye N. Do glucocorticoids contribute to brain aging? Brain Res Brain Res Rev 2001; 37(1-3): 273-86.
24. Swanwick GR, Kirby M, Bruce I, et al. Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry 1998; 155(2): 286-89.
25. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimer Dement 2012; 8(2): 131-68.
26. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112-7.
27. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimer Dement 2007; 3(3): 186-91.
28. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34(1): 2-11.
29. Adams JD Jr. Alzheimer's disease, ceramide, visfatin and NAD. CNS Neurol Disord Drug Targets 2008; 7(6): 492-8.
30. Warren MW, Hynan LS, Weiner MF. Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 2012; 29(1): 151-7.
31. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92(3): 347-55.
32. Goldstein BJ, Scalia R. Adipokines and vascular disease in diabetes. Curr Diab Rep 2007; 7(1): 25-33.
33. Eldor R, Raz I. Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. Diabetes Res Clil Pract 2006; 74(2 Suppl): S3-8.
34. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008; 14(3-4): 222-31.
35. Smith U. Introduction: Symposium on diabetes, inflammation and cardiovascular disease. J Intern Med 2007; 262(2): 142-4.
36. Aubé AC, Blottière HM, Scarpignato C, et al. Inhibition of acetylcholine induced intestinal motility by interleukin 1 beta in the rat. Gut 1996; 39(3): 470-4.
37. Gupta A, Pansari K. Inflammation and Alzheimer's disease. Int J Clin Pract 2003; 57(1): 36-9.
38. Cacabelos R, Barquero M, García P, Alvarez XA, Varela de Seijas E. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol 1991; 13(7): 455-8.
39. Fillit H, Ding WH, Buee L, et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991; 129(2): 318-20.
40. Koivisto AM, Helisalmi S, Pihlajamäki J, et al. Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population. J Neurogenet 2005; 19(3-4): 155-61.
41. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 2006; 8(2): 25.
42. Rosenberg PB. Editorial: cytokine inhibition for treatment of Alzheimer's disease. MedGenMed 2006; 8(2): 24.
43. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53(9): 1937-42.
44. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61(5): 661-6.
45. Marks JL, King MG, Baskin DG. Localization of insulin and type 1 IGF receptors in rat brain by in vitro autoradiography and in situ hybridization. Adv Exp Med Biol 1991; (293): 459-70.
46. Schwartz MW, Figlewicz DF, Kahn SE, et al. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 1990; 11(3): 467-72.
47. Isganaitis E, Lustig RH. Fast food, central nervous system insulin resistance, and obesity. Arterioscler Thromb Vasc Biol 2005; 25(12): 2451-62.
48. Ryu KY, Garza JC, Lu XY, Barsh GS, Kopito RR. Hypothalamic neurodegeneration and adult-onset obesity in mice lacking the Ubb polyubiquitin gene. PNAS 2008; 105(10): 4016-21.
49. Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 2002; 5 Suppl: 1055-7.
50. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63(7): 1187-92.
51. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000; 160(2): 174-80.
52. Areosa SA, Grimley EV. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 2002; (4): CD003804.
53. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18(7): 902-4.
54. Díaz B, Serna J, De Pablo F, de la Rosa EJ. In vivo regulation of cell death by embryonic (pro)insulin and the insulin receptor during early retinal neurogenesis. Development 2000; 127(8): 1641-9.
55. Wu X, Reiter CEN, Antonetti DA, et al. Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner. J Biol Chem 2004; 279(10): 9167-75.
56. Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003; 28(6): 809-22.
57. Watson GS, Peskind ER, Asthana S, et al. Insulin increases CSF Abeta 42 levels in normal older adults. Neurology 2003; 60(12): 1899-903.
58. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272(31): 19547-53.
59. Yan LM, Velkova A, Tatarek-Nossol M, Andreetto E, Kapurniotu A. IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew Chem Int Ed Engl 2007; 46(8): 1246-52.
60. Hernández F, Gómez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol 2010; 223(2): 322-5.
61. Chin PC, Majdzadeh N, D'Mello SR. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 2005; 137(1-2): 193-201.
62. Lee J, Kim MS. The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract 2007; 77(Suppl 1): S49-57.
63. Joh TH, Geghman C, Reis D. Immunochemical demonstration of increased accumulation of tyrosine hydroxylase protein in sympathetic ganglia and adrenal medulla elicited by reserpine. PNAS 1973; 70(10): 2767-71.
64. Kobayashi K. Role of catecholamine signaling in brain and nervous system functions: new insights from mouse molecular genetic study. J Investig Dermatol Symp Proc 2001; 6(1): 115-21.
65. Marco GSD, Colucci JA, Fernandes FB, et al. Diabetes induces changes of catecholamines in primary mesangial cells. Int J Biochem Cell Biol 2008; 40(4): 747-54.
66. Flatmark T, Stevens RC. Structural Insight into the Aromatic Amino Acid Hydroxylases and Their Disease-Related Mutant Forms. Chem Rev 1999; 99(8): 2137-60.
67. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW. Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 2004; 91(5): 1025-43.
68. Haycock JW, Ahn NG, Cobb MH, Krebs EG. ERK1 and ERK2: two microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ. PNAS 1992; 89(6): 2365-9.
69. Ghee M, Baker H, Miller JC, Ziff EB. AP-1: CREB and CBP transcription factors differentially regulate the tyrosine hydroxylase gene. Brain Res Mol Brain Res 1998; 55(1): 101-14.
70. Ichinose H, Suzuki T, Inagaki H, Ohye T, Nagatsu T. Molecular genetics of dopa-responsive dystonia. Biol Chem 1999; 380(12): 1355-64.
71. Martínez A. Evidence for a functionally important histidine residue in human tyrosine hydroxylase. Amino Acids 1995; 9(3): 285-92.
72. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007; 69(6): 1272-6.
73. Zeman M, Jáchymová M, Jirák R, et al. Polymorphisms of genes for brain-derived neurotrophic factor, methylenetetrahydrofolate reductase, tyrosine hydroxylase, and endothelial nitric oxide synthase in depression and metabolic syndrome. Folia Biol 2010; 56(1): 19-26.
74. Chiba M, Suzuki S, Hinokio Y, et al. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metab Clin Exp 2000; 49(9): 1145-9.
75. Serretti A, Macciardi F, Verga M, et al. Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. Am J Med Genet 1998; 81(2): 127-30.
76. Furlong RA, Rubinsztein JS, Ho L, et al. Analysis and metaanalysis of two polymorphisms within the tyrosine hydroxylase gene in bipolar and unipolar affective disorders. Am J Med Genet 1999; 88(1): 88-94.
77. Sullivan JL, Segal DS, Kuczenski RT, Mandell AJ. Propranololinduced rapid activation of rat striatal tyrosine hydroxylase concomitant with behavioral depression. Biol Psychiatry 1972; 4(3): 193-203.
78. Riederer P, Bartl J, Laux G, Grünblatt E. Diabetes type II: a risk factor for depression-Parkinson-Alzheimer? Neurotox Res 2011; 19(2): 253-65.
79. Billingsley ML, Balaban CD, Berresheim U, Kuhn DM. Comparative studies on the distribution of protein-o-carboxylmethyltransferase and tyrosine hydroxylase in rat brain by immunocytochemistry. Neurochem Int 1986; 8(2): 255-65.
80. Pasinetti GM, Osterburg HH, Kelly AB, et al. Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. Brain Res Mol Brain Res 1992; 13(1-2): 63-73.
81. Katori Y, Shibata S, Kawase T, Cho BH, Murakami G. Transient appearance of tyrosine hydroxylase immunoreactive cells in the midline epithelial seam of the human fetal secondary palate. Cleft Palate Craniofac J 2012; 49(4): 414-24.
82. Zhou J, Pliego-Rivero B, Bradford HF, Stern GM, Jauniaux ER. Induction of tyrosine hydroxylase gene expression in human foetal cerebral cortex. Neurosci Lett 1998; 252(3): 215-7.
83. Patankar S, Lazaroff M, Yoon SO, Chikaraishi DM. A novel basal promoter element is required for expression of the rat tyrosine hydroxylase gene. J Neurosci 1997; 17(11): 4076-86.
84. Kim SS, Moon KR, Choi HJ. Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells. Arch Pharm Res 2011; 34(5): 837-45.
85. Lewis DA, Melchitzky DS, Haycock JW. Four isoforms of tyrosine hydroxylase are expressed in human brain. Neuroscience 1993; 54(2): 477-92.
86. Newman JC, Holden RJ. The 'cerebral diabetes' paradigm for unipolar depression. Med Hypotheses 1993; 41(5): 391-408.
87. Habecker BA, Klein MG, Sundgren NC, Li W, Woodward WR. Developmental regulation of neurotransmitter phenotype through tetrahydrobiopterin. J Neurosci 2002; 22(21): 9445-52.
88. Morrison CD, Pistell PJ, Ingram DK, et al. High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling. J Neurochem 2010; 114(6): 1581-9.
89. Morley JE. Nutrition and the brain. Clin Geriatr Med 2010; 26(1): 89-98.
90. Shah RS, Lee HG, Xiongwei Z, et al. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 2008; 62(4): 199-207.
91. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92(5): 1189-96.
92. Kastorini CM, Milionis HJ, Esposito K, et al. The effect of Mediterranean diet on metabolic syndrome and its components: a metaanalysis of 50 studies and 534:906 individuals. J Am Coll Cardiol 2011; 57(11): 1299-313.
93. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60(7): 940-6.
94. Bouzan C, Cohen JT, Connor WE, et al. A quantitative analysis of fish consumption and stroke risk. Am J Prev Med 2005; 29(4): 347-52.
95. He K, Song Y, Daviglus ML, et al. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke 2004; 35(7): 1538-42.
96. Skerrett PJ, Hennekens CH. Consumption of fish and fish oils and decreased risk of stroke. Prev Cardiol 2003; 6(1): 38-41.
97. Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002; 10(3): 279-88.
98. Palacios HH, Yendluri BB, Parvathaneni K, et al. Mitochondrionspecific antioxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets 2011; 10(2): 149-62.
99. Shenk JC, Liu J, Fischbach K, et al. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci 2009; 283(1-2): 199-206.
100. Trieu VN, Uckun FM. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem Biophys Res Commun 1999; 258(3): 685-8.
101. Hou RCW, Chen HL, Tzen JTC, Jeng KCG. Effect of sesame antioxidants on LPS-induced NO production by BV2 microglial cells. Neuroreport 2003; 14(14): 1815-9.
102. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13(3): 100-5.
103. Qin B, Nagasaki M, Ren M, et al. Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. Diabetes Res Clin Pract 2003; 62(3): 139-48.
104. Rabinovitz H, Friedensohn A, Leibovitz A, et al. Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. Int J Vitam Nutr Res 2004; 74(3): 178-82.
105. McCarty MF. Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides. Med Hypotheses 2006; 67(4): 682-97.
106. Aliev G, Palacios HH, Walrafen B, et al. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int J Biochem Cell Biol 2009; 41(10): 1989-2004.
107. Aliev G, Liu J, Shenk JC, et al. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J Cell Mol Med 2009; 13(2): 320-33.
108. Preka Y. Mediterranean Diet Wins Place on UNESCO's "Intangible Cultural Heritage of Humanity". Latest News from Greece, 2010; Available from: http://greece.greekreporter.com/2010/11/18/mediterra nean-diet-included-in-unesco%E2%80%99s-intangible-world-heritage/#!lightbox/0
109. Science Daily 2010; Magnesium supplement helps boost brainpower. Available from: http://www.sciencedaily.com/releases/2010/01/100127121524.htm
110. Palinkas LA, Barrett-Connor E, Wingard DL. Type 2 diabetes and depressive symptoms in older adults: a population-based study. Diabet Med 1991; 8(6): 532-9.
111. Russo-Neustadt A, Zomorodian TJ, Cotman CW. Preserved cerebellar tyrosine hydroxylase-immunoreactive neuronal fibers in a behaviorally aggressive subgroup of Alzheimer's disease patients. Neuroscience 1998; 87(1): 55-61.
112. Dickerson BC, Stoub TR, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011; 76(16): 1395-402.
113. Zhang L, Bruce-Keller AJ, Dasuri K, et al. Diet-induced metabolic disturbances as modulators of brain homeostasis. Biochim Biophys Acta 2009; 1792; (5): 417-22.